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Abstract Phytanoyl-CoA hydroxylase (PhyH) catalyzes the
conversion of phytanoyl-CoA to 2-hydroxyphytanoyl-CoA,
which is the first step in the phytanic acid 
 
a
 
-oxidation path-
way. Recently, several studies have shown that in humans,
phytanic acid 
 
a
 
-oxidation is localized in peroxisomes. In
rat, however, the 
 
a
 
-oxidation pathway has been reported to
be mitochondrial. In order to clarify this differential subcel-
lular distribution, we have studied the rat PhyH protein. We
have purified PhyH from rat liver to apparent homogeneity
as judged by SDS-PAGE. Sequence analysis of two PhyH
peptide fragments allowed cloning of the rat 
 
PHYH
 
 cDNA
encoding a 38.6 kDa protein. The deduced amino acid
sequence revealed strong homology to human PhyH includ-
ing the presence of a peroxisome targeting signal type 2
(PTS2). Heterologous expression of rat 
 
PHYH
 
 in 
 
Saccharo-
myces cerevisiae
 
 yielded a 38.6 kDa protein whereas the
PhyH purified from rat liver had a molecular mass of 35
kDa. This indicates that PhyH is probably processed in rat
by proteolytic removal of a leader sequence containing the
PTS2. This type of processing has been reported in several
other peroxisomal proteins that contain a PTS2. Subcellular
localization studies using equilibrium density centrifugation
showed that PhyH is indeed a peroxisomal protein in rat.
The finding that PhyH is peroxisomal in both rat and humans
provides strong evidence against the concept of a differen-
tial subcellular localization of phytanic acid 
 
a
 
-oxidation in
rat and human.
 
—Jansen, G. A., R. Ofman, S. Denis, S. Ferdi-
nandusse, E. M. Hogenhout, C. Jakobs, and R. J. A. Wan-
ders.
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Supplementary key words
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•
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•
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•
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Fatty acids containing a methyl group at the 3-position
cannot be 
 
b
 
-oxidized directly but first require the oxida-
tive removal of the terminal carboxyl-group in a process
 
called 
 
a
 
-oxidation. The product of this pathway is a 2-
methyl fatty acid which then can undergo 
 
b
 
-oxidation.
Most studies on the mechanism of 
 
a
 
-oxidation have
been performed with phytanic acid (3,7,11,15-tetrameth-
ylhexadecanoic acid) as this fatty acid accumulates in
patients suffering from Refsum’s disease (RD), a rare in-
born error of metabolism. For a long time it was thought
that 
 
a
 
-oxidation of phytanic acid involved the free fatty
acid and not the CoA-ester. Studies by Watkins, Howard,
and Mihalik (1), however, revealed that phytanoyl-CoA is
the true substrate for 
 
a
 
-oxidation. Mihalik, Rainville, and
Watkins (2) showed that the first step in the 
 
a
 
-oxidation
process, the conversion of phytanoyl-CoA into 2-hydroxy-
phytanoyl-CoA is catalyzed by phytanoyl-CoA hydroxylase
(PhyH). This enzyme is a 2-oxoglutarate-dependent dioxy-
genase which requires Fe
 
2
 
1
 
 and ascorbate as cofactors
(Scheme 1). In humans, PhyH is localized in peroxisomes
(3) and is directed to these organelles by means of a per-
oxisome targeting signal type 2 (PTS2) (4). We have found
that PhyH is deficient in patients with RD (5) due to muta-
tions in the corresponding gene (3).
The product of the hydroxylation reaction catalyzed by
PhyH, 2-hydroxyphytanoyl-CoA, undergoes cleavage to yield
pristanal and formyl-CoA (6 –8). Pristanal is converted
to pristanic acid (2,6,10,14-tetramethylpentadecanoic
acid), which after activation to its CoA-ester can undergo
 
b
 
-oxidation in peroxisomes (9, 10).
Although the individual enzymatic steps of the 
 
a
 
-
oxidation pathway have recently been resolved, there is
still considerable debate about the subcellular localization
 
Abbreviations: PhyH, phytanoyl-CoA hydroxylase (phytanoyl-CoA,
2-oxoglutarate dioxygenase); 
 
PHYH
 
, phytanoyl-CoA hydroxylase cDNA
sequence; PTS, peroxisome targeting signal; RD, Refsum’s disease;
AGT, alanine glyoxylate aminotransferase.
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of phytanic acid 
 
a
 
-oxidation. According to some authors,
phytanic acid 
 
a
 
-oxidation is mitochondrial (9, 11–15),
whereas others reported a peroxisomal (16–18) or micro-
somal localization (19, 20). Moreover, involvement of cy-
tosolic components has also been suggested (21).
Singh and coworkers (22) reported that 
 
a
 
-oxidation is
peroxisomal in humans and mitochondrial in rat. Such a
differential localization of an enzyme between species is
not unprecedented. One example is alanine glyoxylate
aminotransferase (AGT) (23). In humans, baboons, ma-
caques, rabbits, and guinea pigs, AGT is solely peroxisomal.
In rats, marmosets, mice, hamsters, and opossums, AGT is
approximately evenly distributed between peroxisomes
and mitochondria, whereas in cats and dogs a primarily mi-
tochondrial localization is observed (see ref. 23 for review).
As different targeting signals are required for directing
proteins to organelles such as mitochondria and peroxi-
somes, one would expect the presence of a mitochondrial
targeting signal in rat PhyH. In order to resolve this issue,
we have purified PhyH from rat liver and cloned the
 
PHYH
 
 cDNA. Expression of rat PhyH in 
 
S. cerevisiae
 
 re-
sulted in high PhyH activity. The deduced amino acid se-
quence revealed strong homology with human PhyH in-
cluding the presence of a PTS2 sequence. These findings
strongly suggested that in rat PhyH is also localized in per-
oxisomes. Indeed, subsequent equilibrium density centrif-
ugation experiments provided conclusive evidence for the
peroxisomal localization of PhyH in rat.
MATERIALS AND METHODS
 
Materials
 
[1-
 
14
 
C]2-oxoglutarate (50 Ci
 
?
 
mol
 
2
 
1
 
) was purchased from Du-
Pont NEN, ‘s-Hertogenbosch, The Netherlands. Prior to use it
was diluted with unlabeled 2-oxoglutarate to obtain a solution of
1 m
 
m
 
, 4.5 Ci
 
?
 
mol
 
2
 
1
 
. Nycodenz was from Nycomed Pharma AS,
Oslo, Norway. Octyl Sepharose CL-4B, S-Sepharose FF, phenyl
Sepharose HP, PBE 94, and Polybuffer 96 were from Pharmacia
Biotech Benelux, Roosendaal, The Netherlands. The 5 ml CHT-
II Econo-pac cartridge and goat anti-rabbit IgG coupled to alka-
line phosphatase were from Bio-Rad Laboratories, Veenendaal,
The Netherlands. Pefabloc was from Boehringer Mannheim NL,
Almere, The Netherlands. Freund’s complete adjuvant and
Freund’s incomplete adjuvant were from Gibco-Life Technolo-
gies, Breda, The Netherlands.
All other reagents were of analytical grade.
 
Phytanoyl-CoA synthesis
 
Phytanoyl-CoA was synthesized from phytanic acid as de-
scribed (24). [1-
 
14
 
C]phytanoyl-CoA was synthesized enzymatically
from [1-
 
14
 
C]phytanic acid as previously described (25).
 
PhyH activity measurement
 
PhyH activity measurements were performed using two differ-
ent methods. Method 1: [1-
 
14
 
C]phytanoyl-CoA was used as sub-
strate and the amount of [1-
 
14
 
C]2-hydroxyphytanoyl-CoA pro-
duced was determined using a radiochemical HPLC method as
described elsewhere (25).
Method 2: PhyH activity measurement was based on the pro-
duction of 
 
14
 
CO
 
2
 
 from [1-
 
14
 
C]2-oxoglutarate, which acts as co-
substrate in the enzymatic conversion of phytanoyl-CoA to 2-
hydroxyphytanoyl-CoA (Scheme 1). After optimizing the assay
for partially purified subcellular fractions (see Results section),
PhyH activity measurements were performed as follows. A (par-
tially) purified protein preparation was added to a reaction mix-
ture containing 50 m
 
m
 
 Tris-HCl, 0.2 m
 
m
 
 dithiothreitol, 1.5 
 
m
 
m
 
BSA, 10 m
 
m
 
 ATP, 25 
 
m
 
m
 
 phytanoyl-CoA, 1 m
 
m
 
 ascorbate, 1 m
 
m
 
ammonium iron[II]sulfate, 0.1 m
 
m
 
 [1-
 
14
 
C]2-oxoglutarate (4.5
Ci
 
?
 
mol
 
2
 
1
 
), final pH 7.5, total reaction volume 250 
 
m
 
l. The small
glass reaction tubes, together with an 1.5-ml Eppendorf reaction
tube containing 0.5 ml 2 
 
m
 
 NaOH, were placed in a 20-ml glass
vial which was closed air tight with a screw-cap equipped with a
septum, and incubated at 37
 
8
 
C for 1 h. The reactions were termi-
nated by adding 100 
 
m
 
l 1.3 
 
m
 
 perchloric acid through the septum
using a Hamilton syringe. 
 
14
 
CO
 
2
 
 was trapped overnight at 4
 
8
 
C in
the NaOH solution which was analyzed by liquid scintillation
spectrometry.
 
Purification of PhyH from rat liver
 
All PhyH activity measurements were carried out according to
method 2 as described above.
 
Step 1: isolation of peroxisomes from rat liver.
 
Peroxisomes were
isolated from 8 male Wistar rats that were fed a standard labora-
tory diet supplemented with 1.0% (w/w) diethylhexylphthalate
(DEHP) for 9 days. Livers were minced and homogenized in an
ice-cold medium containing 250 m
 
m
 
 sucrose, 5 m
 
m
 
 MOPS, 2.5
m
 
m
 
 EDTA, pH 7.4. This homogenate was used to prepare a puri-
fied peroxisomal fraction using discontinuous Nycodenz centrif-
ugation essentially as described previously (26) with slight modi-
fications (27).
 
Step 2: octyl Sepharose CL-4B hydrophobic interaction chromatogra-
phy.
 
The purified peroxisomes obtained in step 1 were applied
onto an octyl Sepharose CL-4B column (2.6 
 
3
 
 7 cm) equilibrated
with a buffer containing 0.2% CHAPS, 5 m
 
m
 
 dithiothreitol, 20
m
 
m
 
 potassium phosphate, 1 
 
m
 
 KCl, pH 7.4, at a flow rate of 0.8
ml
 
?
 
min
 
2
 
1
 
. The column was subsequently washed with the same
buffer to obtain 1100 ml eluent containing unabsorbed proteins.
PhyH activity measurement revealed that all activity was present
in this wash-fraction. This fraction was concentrated using an
Amicon YM10 cut-off filter (Millipore NL, Etten-Leur, The Neth-
erlands) to obtain a volume of 400 ml, and dialyzed against 2
times 5 liters buffer solution containing 20 m
 
m
 
 Tris-HCl plus 10%
(v/v) glycerol, pH 7.6. The final volume was 510 ml.
 
Step 3: S-Sepharose FF cation exchange chromatography.
 
Five hun-
dred ten ml of the dialyzed fraction containing the unbound pro-
teins obtained in step 2 was applied onto an S-Sepharose FF col-
umn (2.6 
 
3
 
 10 cm) equilibrated with a buffer containing 20 m
 
m
 
Tris-HCl, 10% (v/v) glycerol, 50 m
 
m
 
 potassium chloride, pH 7.6.
Absorbed proteins were eluted with a linear gradient of potas-
sium chloride (50–250 m
 
m
 
) at a flow rate of 2.5 ml
 
?
 
min
 
2
 
1
 
. Frac-
tions of 10 ml were collected and assayed for PhyH activity.
 
Step 4: hydroxy apatite chromatography.
 
Fractions 18–22 of step 3
were pooled, diluted with 125 ml 10 m
 
m
 
 sodium phosphate, 10%
(v/v) glycerol, 5 m
 
m
 
 dithiothreitol, pH 7.4, and loaded on top of
a hydroxyapatite column equilibrated with a buffer containing 50
m
 
m
 
 NaP
 
i
 
, 10% (v/v) glycerol, 5 m
 
m
 
 dithiothreitol, pH 7.4, and
eluted with a linear sodium phosphate gradient (50–200 mM) at
a flow rate of 0.75 ml
 
?
 
min
 
2
 
1
 
. Fractions of 3 ml were collected
and assayed for PhyH activity.
 
Step 5: phenyl Sepharose HP hydrophobic interaction chromatogra-
phy.
 
Fractions 6–7 of step 4 were pooled and ammonium phos-
phate was added to a final concentration of 0.8 
 
m
 
, and applied to a
phenyl Sepharose HP column (1.0 
 
3
 
 2.8 cm) equilibrated with
a buffer containing 0.8 
 
m
 
 ammonium phosphate, 10% (v/v) glycerol,
5 m
 
m
 
 dithiothreitol, pH 7.6. Elution was carried out by a linear de-
crease of the ammonium phosphate concentration from 0.8–0.1 
 
m
 
 at
a flow rate of 0.85 ml
 
?
 
min
 
2
 
1
 
. Fractions of 1.7 ml were collected.
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PBE 94 chromatofocusing
 
The pI of PhyH was determined by chromatofocusing using a
2 ml PBE 94 (1.0 
 
3
 
 5.0 cm) column, equilibrated with 25 m
 
m
 
 2-
amino ethanol–acetate, 10% (v/v) glycerol, pH 9.4. One ml of
the dialyzed fraction obtained in step 2 of the PhyH purification
was applied onto the column, followed by 1 ml of 25 m
 
m
 
 2-amino
ethanol–acetate, 10% (v/v) glycerol, pH 9.4. Elution was carried
out using Polybuffer 96–acetate, 10% (v/v) glycerol, pH 6.0. Im-
mediately after collection of each 1 ml fraction, the pH was deter-
mined and subsequently neutralized using 0.2 ml 0.5 
 
m
 
 Tris-HCl,
pH 7.5. PhyH activity was determined using method 2 as de-
scribed above.
 
Protein sequencing
 
After purification of PhyH from rat liver, an aliquot of the pro-
tein solution was digested with Lys-C to obtain peptide frag-
ments. The purified PhyH as well as the Lys-C digest were sub-
jected to SDS-PAGE and blotted onto an Immobilon-P membrane
(Millipore NL, Etten-Leur, The Netherlands) using a buffer con-
taining 40 m
 
m
 
 Tris-HCl, 40 m
 
m boric acid, 20% (v/v) methanol,
0.1 g?L21 (w/v) SDS, pH 8.6, for 1 h at 1.5 mA?cm22. The immo-
bilized polypeptides were visualized using Coomassie Blue R250
and subsequently subjected to N-terminal amino acid sequencing
using a Procise 494 protein sequencer.
Cloning of rat PHYH
Using first strand cDNA from rat liver as template, the 59-half
of the rat PHYH cDNA was amplified by PCR using ‘-21M13 for-
ward’- and ‘M13 reverse’-tagged primers mPH-27f (sense 59-TGT
AAA ACG ACG GCC AGT GCA GAG TTT CGT CTG CTG GC-
39) and mPH643r (antisense 59-CAG GAA ACA GCT ATG ACC
CTT TGT GGG TAC CTG GAA GC-39), based on the murine
PHYH sequence (GenBank accession number AF023463). Subse-
quent sequence analysis of this fragment of both sense and anti-
sense strands was performed using ‘-21M13 forward’- and ‘M13
reverse’ fluorescent primers, respectively, on an Applied Biosys-
tems 377A automated DNA sequencer following the manu-
facturer’s protocols. The 39-end of the rat PHYH sequence was
obtained using the Marathon cDNA 39-RACE kit (Clontech Labo-
ratories GmbH, Heidelberg, Germany). The ‘-21M13 forward’-
tagged gene specific primers PH557f (sense 59-TGT AAA ACG
ACG GCC AGT GCA ACC TAA TTG TTT GTG C-39) and PH649f
(sense 59-TGT AAA ACG ACG GCC AGT CAG ACT ATC ATC
CCA GTA CC-39) were used and the obtained fragment was sub-
sequently sequenced.
Heterologous expression in S. cerevisiae
The complete coding sequence of rat PHYH was amplified
from rat liver cDNA using XbaI and HindIII tagged primers (59-
AAA TCT AGA AAA ATG ACT ATA CGG CGC GC-39 and 59-AAA
AAG CTT TCA AAG GTT TAT TCT TTC TCC-39, respectively)
and cloned into the plasmid pGEM-T (Promega, Leiden, The
Netherlands) to obtain pPHYHr. The PHYH sequence was subse-
quently verified by sequence analysis using T7 and SP6 primers.
The obtained PHYH clone was digested with XbaI and HindIII
and subcloned into the XbaI and HindIII sites of the yeast ex-
pression plasmids pEL26 (high copy plasmid, containing 2 m
sequence) and pEL30 (low copy plasmid, containing CEN-
sequence) (28), in both plasmids under the transcriptional con-
trol of the oleate inducible promoter pCTA1. The expression
constructs and, as a control, the vectors pEL26 and pEL30 were
transformed into S. cerevisiae strain BJ1991 (MATa, leu2, trp1,
ura3–52, prb1–1122, pep4–3) (29). Transformants were grown in
minimal essential medium containing 3 g?L21 glucose and 6.7
g?L21 yeast nitrogen base without amino acids (Difco Laborato-
ries, Detroit MI) supplemented with appropriate amino acids at
308C. In order to induce expression, cells were harvested by cen-
trifugation and transferred into a medium containing 1.2 g?L21
oleic acid, 1.2 g?L21 Tween-40, 5 g?L21 potassium phosphate
(pH 6.0), 3 g?L21 yeast extract, and 5 g?L21 peptone. Cells were
grown at 308C and harvested by centrifugation after the culture
reached a spectrophotometrical absorbance at 600 nm of about
0.5. The cells were resuspended in 250 ml buffer containing 20
mm Tris-HCl, pH 7.5, 5 mm dithiothreitol, 1 mg?ml21 leupeptin, 2
mg?ml21 Pefabloc and 10% (v/v) glycerol. After addition of 200
ml glass beads, the suspension was vortexed for 30 min at 48C,
centrifuged for 2 min at 12,000 g at 48C, and the clear lysate con-
taining rat PhyH was taken for PhyH activity measurements and
further experiments.
Generation of anti-PhyH antiserum
Female New Zealand white rabbits were primed with 20 mg pu-
rified rat PhyH in 0.8 ml PBS mixed with an equal volume of
Freund’s complete adjuvant. After 2 weeks the immunization was
followed by a boost injection of 20 mg of PhyH mixed with Freund’s
incomplete adjuvant. Two more boost injections were given at 4-
week intervals. Eight days after each boost injection a 10-ml
blood sample was taken, and serum was prepared.
SDS-PAGE and immunoblot analysis
Samples were subjected to SDS-PAGE on a 10% polyacryl-
amide gel and blotted onto a nitrocellulose filter. Nonspecific
binding sites were blocked for 1 h using a PBS solution contain-
ing 1 g?L21 Tween-20 (PBST), supplemented with 30 g?L21 non-
fat dried milk (NFDM). Primary (polyclonal anti-PhyH) and sec-
ondary (goat anti-rabbit IgG coupled to alkaline phosphatase)
antibody incubations were performed in PBST. After each incu-
bation, the blots were washed extensively in 3 g?L21 NFDM/
PBST. Antigen–antibody complexes were visualized using alka-
line phosphatase staining in a buffer containing 0.1 m Tris-HCl
(pH 9.5), 0.1 m NaCl, 5 mm MgCl2, 0.33 g?L21 4-nitro blue tetra-
zolium chloride, 0.17 g?L21 5-bromo-4-chloro-3-indolyl-phos-
phate (disodium salt).
Subcellular fractionation of rat liver
For subcellular fractionation studies, fresh rat livers were
minced, washed several times in ice-cold phosphate-buffered sa-
line, and homogenized in a buffer containing 250 mm sucrose, 5
mm MOPS, and 0.1 mm EGTA, final pH 7.4. Homogenates were
centrifuged 10 min at 600 g at 48C to produce a postnuclear su-
pernatant. This supernatant was subjected to differential centrif-
ugation exactly as described before (30) to produce a light mito-
chondrial fraction. Subfractionation of this light mitochondrial
fraction using equilibrium density gradient centrifugation was per-
formed as described before (31). Catalase (peroxisomes) (32),
glutamate dehydrogenase (mitochondria) (33), esterase (micro-
somes) (30), and lactate dehydrogenase (34) (cytosol) were used
as marker enzymes, and were measured as described. Aliquots of
the subcellular fractions were taken, protein was precipitated us-
ing 100 g?L21 trichloroacetic acid and dissolved in Tris buffer,
followed by SDS-PAGE/immunoblot analysis.
RESULTS
PhyH activity measurement using [1-14C]2-oxoglutarate
In previous studies, measurement of PhyH activity was
based on the conversion of radiolabeled phytanoyl-CoA
into 2-hydroxyphytanoyl-CoA, using a radiochemical HPLC
method allowing the detection of these CoA-esters (25).
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As this assay is very time consuming and therefore not
convenient for measurement of large series of samples,
we have developed an assay based on the conversion of
[1-14C]2-oxoglutarate into succinate and 14CO2. This con-
version takes place stoichiometrically with the hydroxyla-
tion reaction (Scheme 1), and is carried out analogous to
assay systems for other 2-oxoglutarate-dependent dioxyge-
nases (35–37). PhyH activity measurements in crude liver
homogenates, using this assay, showed a very high rate of
14CO2 production, which was independent on the pres-
ence of phytanoyl-CoA, Fe21, or ascorbate, the substrate
and obligatory cofactors of PhyH. Cell fractionation stud-
ies revealed that this 14CO2 production occurred mainly
in the mitochondrial fraction, and it is likely that decar-
boxylation of 2-oxoglutarate is caused by the a-ketoglu-
tarate dehydrogenase complex. When purified peroxi-
somes were used for the assay, production of 14CO2 was
completely dependent on the presence of phytanoyl-CoA
and Fe21, whereas omission of ascorbate decreased the
production of 14CO2 to about one-third of the activity ob-
served in the presence of 1 mm ascorbate (Table 1). The
optimal pH for PhyH activity was 7.5 and the reaction was
linear with time for 1 h and linear with protein up to at
least 0.5 mg?ml21 (data not shown).
When this 14CO2 release assay was compared to the assay
based on the measurement of the product of the hydroxy-
lation reaction, [1-14C]2-hydroxyphytanoyl-CoA, similar
activities were found, and cosubstrate and cofactor re-
quirements were essentially the same (Table 1).
Purification of PhyH from rat liver
Stability of PhyH activity during the purification. Enzymatic
activity of the PhyH protein in crude or partially purified
fractions (liver homogenate or purified peroxisomes) was
stable upon storage at 48C. However, in more purified
fractions, PhyH activity rapidly declined when stored at
48C and even more at 2208C or 2808C, the latter proba-
bly also due to freeze-thawing effects on the preparation.
Loss of enzymatic activity could only partially be pre-
vented when 10% (v/v) glycerol and 5 mm dithiothreitol
were added to all buffers used.
Purification of PhyH from rat liver peroxisomes. When rat
liver peroxisomes were subjected to octyl-Sepharose CL-
4B chromatography, all PhyH activity was present in the
wash fraction (data not shown). S-Sepharose chromatogra-
phy showed that all PhyH activity was bound to the column
and eluted as a single peak upon increasing the concentra-
tion of potassium chloride (data not shown). SDS-PAGE
Scheme 1. Phytanoyl-CoA hydroxylase catalyzes the conversion of phytanoyl-CoA to 2-hydroxyphytanoyl-
CoA. This enzyme is a 2-oxoglutarate-dependent dioxygenase which requires Fe21 and ascorbate as cofactors.
TABLE 1. Cofactor requirements for PhyH activity measurements 
in purified rat liver peroxisomes according to the newly
developed method using 14CO2 measurement and
the original HPLC based method (see ref. 25)
PhyH Activity
Component 
Omitted from the
Reaction Medium 14CO2 2-Hydroxyphytanoyl-CoA
nmol?h21?mg21
None 12.30 15.40
Phytanoyl-CoA <0.05 <0.05
Fe21 <0.05 <0.05
Ascorbate 4.03 5.92
PhyH activity was measured according to the newly developed
method (see Materials and Methods) using 14CO2 production as a mea-
sure of activity (left column), or the method as previously described
(25) using the formation of [1-14C]2-hydroxyphytanoyl-CoA as a mea-
sure of PhyH activity (right column). Values represent the mean of two
separate experiments.
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analysis of the fractions obtained by hydroxyapatite chro-
matography revealed that one protein band (apparent
molecular mass 35 kDa) co-eluted exactly with PhyH activ-
ity, while a 33 kDa protein with a slightly different elution
pattern was present in the fractions containing most PhyH
activity (Fig. 1A, B). Using phenyl-Sepharose hydrophobic
interaction chromatography, these two proteins could be
separated. PhyH activity co-eluted again with the 35 kDa
protein (Fig. 1C, D).
Cloning of the rat PHYH cDNA
After purification of the PhyH protein from rat liver,
both the intact protein as well as a fragment obtained after
Lys-C digestion were subjected to N-terminal protein se-
quencing. The amino-terminus of the purified protein had
the following sequence: SGPASPANFXPEQFQYXLDN.
This sequence was used to screen the EST database for
cDNA clones homologous to this polypeptide, and previ-
ously led to the identification of the human PHYH cDNA
(4). The amino acid sequence from the fragment obtained
after Lys-C treatment (MYH(G/Q)IQDYD) showed very
high homology to the deduced human PhyH sequence
(70% identity, 100% similarity when conservative amino
acid substitutions are considered). Using a different strat-
egy, Mihalik and coworkers (38) identified both the hu-
man and murine PHYH cDNAs.
Searching the EST and genomic databases, no homolo-
gous sequences derived from rat tissues were found. In
order to identify the rat PHYH cDNA sequence, primers
based on the murine PHYH sequence were used to amplify
the 59-end of the PHYH sequence using first strand cDNA
from rat liver as template. The 39-end of the sequence was
obtained using the 39-RACE technique. The coding se-
quence of rat PHYH contained 1014 nucleotides, encod-
ing a 338 amino acid protein (Fig. 2). The calculated mass
of the rat PhyH was 38.6 kDa. The deduced amino acid se-
quence did not contain a mitochondrial targeting signal.
However, a PTS2 sequence was found near the 59-end of
the open reading frame (Fig. 2). This PTS2 has already
been found in both human and murine PhyH, strongly
suggesting a peroxisomal localization. The deduced amino
acid sequence of PhyH showed very high homology to
both human and murine PhyH (Fig. 3).
Based on the observation that amino terminal sequenc-
ing of purified rat PhyH revealed a sequence identical to
amino acids 31–50 rather than 1–20, we have suggested
earlier that in vivo amino acids 1–30 are removed, probably
by proteolytic cleavage (4). This type of post-translational
modification which involves removal of the PTS2 containing
leader sequence has been reported for several PTS2-
containing peroxisomal proteins, including 3-keto-acyl-CoA
thiolase (39, 40) and alkyl-dihydroxyacetonephosphate syn-
Fig. 1. Purification of PhyH from rat liver: step 4, hydroxy apatite chromatography (panels A, B), and step 5, phenyl Sepharose chroma-
tography (panels C, D). Column fractions were separated by 10% SDS-PAGE followed by silver staining (A, C). PhyH activity measurements
in the column fractions (B, D) were performed according to method 2 as described in Materials and Methods.
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thase (41). Experimental support for this idea was ob-
tained by chromatofocusing, which showed that the pI of
rat liver PhyH is 8.5 (Fig. 4). The calculated pI based on
the translation of the complete open reading frame was
8.8. However, when the presumed leader sequence was re-
moved, the calculated pI was 8.5.
Heterologous expression of rat PHYH in S. cerevisiae
When lysates were prepared from the yeast S. cerevisiae,
no PhyH activity could be detected in both wild-type and
yeast transformed with the ‘empty’ pEL26 and pEL30 ex-
pression vectors. When the coding sequence of rat PHYH
was expressed, a high PhyH activity was measured in the
Fig. 2. Rat PHYH cDNA sequence and deduced amino acid sequence. The PTS2 sequence at amino acids
9–17 is double underlined. The peptide fragment identified by N-terminal amino acid sequencing of puri-
fied PhyH (underlined, at position 31–50) indicates the amino-terminus of the PhyH protein after removal
of the PTS2 leader sequence. Amino acid sequencing of a peptide fragment obtained after Lys C treatment
of PhyH revealed a sequence identical to amino acids 232–240 (underlined).
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yeast lysate (6.1 and 35.1 pmol?h21?mg21 in the low copy
and high copy expression constructs, respectively). Immu-
noblot analysis showed that no PhyH could be detected in
lysates from yeast transformed with the control vectors, but
when PhyH was expressed, an immuno reactive protein of
38 kDa was detected. Analysis of rat liver homogenate or
PhyH purified from rat liver showed a 35 kDa protein band
(Fig. 5). These findings provided further evidence for the
removal of the PTS2-containing leader sequence.
Subcellular localization of PhyH
When rat liver homogenate was subjected to differential
centrifugation, almost all PhyH activity was present in the
light mitochondrial (L) fraction, as was catalase, a peroxi-
somal marker enzyme (data not shown). In order to pro-
vide conclusive evidence for the peroxisomal localization
of PhyH, a light mitochondrial fraction was subjected to
equilibrium density centrifugation, and in all fractions
marker enzyme activities were determined (Fig. 6). The
Fig. 3. Comparison of the deduced PhyH amino acid sequences from man, rat, and mouse. Identical
amino acid residues are indicated in shaded boxes.
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distribution of PhyH was determined using SDS-PAGE/
immunoblot analysis. Most PhyH was detected in the bottom
fractions of the gradient, co-localizing with the peroxi-
somal marker enzyme catalase, indicating a peroxisomal
localization of PhyH in rat liver.
Genbank accession number
The rat PHYH sequence was submitted to the Genbank
database and was assigned the accession number AF121345.
DISCUSSION
For many years both the structure and the subcellular
localization of the phytanic acid a-oxidation pathway were
Fig. 4. PBE 94 Chromatofocusing of rat liver PhyH. An aliquot of
the dialyzed wash-fraction obtained after octyl-Sepharose chroma-
tography was subjected to chromatofocusing from pH 9–6 (s), and
PhyH activity (d) was determined according to method 2 (see Ma-
terials and Methods).
Fig. 5. Immunochemical detection of rat PhyH in liver homoge-
nate and in lysates from transformed yeast expressing rat PhyH. Rat
liver homogenate (lane 3), purified PhyH (lane 2), and lysates from
yeast transformed with the PhyH expression vector (lane 1) or the
‘empty’ vector (lane 4) were separated by 10% SDS-PAGE and im-
munoblot analysis was performed as described in Materials and
Methods. M, molecular weight marker.
Fig. 6. Subcellular localization of rat PhyH. Rat liver was sub-
jected to differential centrifugation to obtain a light mitochondrial
fraction. This fraction was subfractionated using equilibrium den-
sity centrifugation and marker enzyme activities were measured in
each fraction. Activities are expressed as percentage of the total ac-
tivity present in the gradient. LDH, lactate dehydrogenase (cyto-
sol); Est, esterase (microsomes); GDH, glutamate dehydrogenase
(mitochondria); Cat, catalase (peroxisomes). The distribution of
PhyH was determined by SDS-PAGE/immunoblot analysis.
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obscure. However, recent studies have resolved the indi-
vidual enzymatic steps involved in phytanic acid a-oxida-
tion, including activation of phytanic acid to phytanoyl-
CoA followed by 1) hydroxylation of phytanoyl-CoA to
2-hydroxyphytanoyl-CoA catalyzed by PhyH, 2) cleavage of
2-hydroxyphytanoyl-CoA into pristanal and formyl-CoA,
and 3) oxidation of pristanal to pristanic acid.
With respect to the subcellular localization of the phy-
tanic acid a-oxidation pathway, Tsai, Avigan, and Stein-
berg (11) were the first to suggest a mitochondrial local-
ization. However, this work was done at a time of little
awareness of the existence of peroxisomes. The finding
that phytanic acid a-oxidation is deficient in cell lines
from patients with Zellweger syndrome in which no func-
tional peroxisomes are present led Poulos, Sharp, and
Whiting (42) to suggest a peroxisomal localization. Subse-
quent studies in rat liver (9, 12, 14, 15) and human liver
(9, 13) showed a mitochondrial localization. Huang and co-
workers (19, 20) even proposed phytanic acid a-oxidation
to be microsomal. Yet another view was held by Singh and
coworkers (22), who suggested phytanic acid a-oxidation
to be mitochondrial in rat but peroxisomal in humans. It
is well known that the subcellular localization of an en-
zyme may differ among species. For instance, alanine gly-
oxylate aminotransferase (AGT) is equally divided be-
tween mitochondria and peroxisomes in rat, whereas in
humans it is exclusively peroxisomal. This dual compart-
mentalization in rat is explained by the fact that the rat
ATG gene has two transcription initiation sites producing
two different mRNAs. The ORF of the shorter transcript
encodes a protein with a C-terminal PTS1 (sequence:
NKL), which directs this protein to peroxisomes. The
longer transcript codes for a protein which contains an N-
terminal extension including a mitochondrial targeting
sequence, and this protein is directed to mitochondria.
Apparently, the mitochondrial targeting signal present in
the longer AGT protein overrules the PTS1. In humans,
the transcription initiation site for the longer transcript
has been lost during evolution. Thus, only the shorter
transcript is produced, explaining the exclusive peroxiso-
mal localization of AGT in humans.
In order to determine whether different targeting signals
are present on the PhyH from rat and human, we have
cloned the rat PHYH cDNA. Analysis of the deduced
amino acid sequence of rat PhyH in comparison to the
human PhyH revealed no known mitochondrial targeting
signal, but instead a PTS2 located near the N-terminus was
found in both species. Our subsequent activity measure-
ments in subcellular fractions show a strict peroxisomal
localization of PhyH in rat liver.
The question arises what the reason is for the different
results obtained in studies performed during the last de-
cades. An important point may be that all these studies
were performed at times when the cofactor requirements
for PhyH, the first step of phytanic acid a-oxidation, were un-
known. Indeed, PhyH is completely dependent on the pres-
ence of the unusual components Fe21 and 2-oxoglutarate. In
addition, the absence of ascorbate severely decreases its
activity (3). Careful inspection of the reaction conditions
used in all studies performed before the discovery of
PhyH in 1995, reveals that 2-oxoglutarate was not in-
cluded in the reaction media used (1, 9, 11–19, 21, 22, 31,
43–53). This immediately explains the very low rates of
[1-14C]phytanic acid a-oxidation found in homogenates
and purified organellar fractions when compared to in-
tact hepatocytes. Indeed, in our earlier studies we found a
high rate of phytanic acid a-oxidation (27.7 pmol?min21?
mg21 protein) in isolated rat hepatocytes, whereas the ac-
tivity in homogenates prepared from the same livers a rate
of only 1.1 pmol?min21?mg21 protein was found. Similar
low rates have been reported in all other studies per-
formed before 1995 (1, 11–19, 21, 22, 31, 43–53).
The second implication of the lack of 2-oxoglutarate in
the reaction medium is that the low a-oxidation rate ob-
served is probably not mediated by PhyH. Yet another im-
portant issue to be mentioned is that in most studies the
amount of 14CO2 produced from [1-14C]phytanic acid is
taken as a measure of a-oxidation activity. However, CO2
is not a direct product of the a-oxidation: in the second
step of the a-oxidation pathway, 2-hydroxyphytanoyl-CoA
is converted to pristanal and formyl-CoA. The latter prod-
uct is converted to formic acid, and subsequently to CO2
(45). The subcellular localization of the enzyme(s) in-
volved in the conversion of formyl-CoA to CO2 are still un-
known, but a considerable amount of the formic acid pro-
duced is not converted to CO2 (45). Therefore, the CO2
produced can be regarded as an unreliable, indirect mea-
sure of the first two steps of phytanic acid a-oxidation.
Based on these arguments we conclude that all results
from previous studies on phytanic acid a-oxidation in ho-
mogenates and subcellular factions need to be revised.
The recent elucidation of the a-oxidation pathway now
enables studies on the individual enzymes catalyzing the
three steps of phytanic acid a-oxidation in various species.
In this report we have provided conclusive evidence that
PhyH, the enzyme catalyzing the first step of phytanic acid
a-oxidation, is localized in peroxisomes in both rat and
humans.
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